
Jazz Pharmaceuticals plc: updates and filings
Price
$238.83
November 19, 2026Market cap $15.0B
What Ploutos Investor adds for Jazz Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 2, 2026next Feb 3, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
- 31MonDealMaterial agreement entered, new material financial obligation, unregistered sale of shares, other material eventsDocument
- 25TueOtherOther material eventsDocument
- 10MonDealMaterial agreement enteredDocument
- 3MonReportQuarterly report · for the period to Jun 30, 2026Document
- 3MonResultsResults of operationsDocument
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 2, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 2, 2026Results of operationsForm8-K
- Oct 26, 2026Results of operationsForm8-K
- Oct 9, 2026Officer or director changeForm8-K
- Sep 23, 2026Material agreement entered, new material financial obligationForm8-K
- Sep 15, 2026Regulation FD disclosureForm8-K
- Aug 31, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, other material eventsForm8-K
- Aug 25, 2026Other material eventsForm8-K
- Aug 10, 2026Material agreement enteredForm8-K
- Aug 10, 2026Regulation FD disclosureForm8-K
- Aug 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 3, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Results of operationsForm8-K
- Jul 24, 2026Shareholder voteForm8-K
- Jul 14, 2026Additional annual meeting materialFormDEFA14A
- Jun 8, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Jun 8, 2026Additional annual meeting materialFormDEFA14A
- Jun 8, 2026Annual meeting proxy statementFormDEF 14A
- May 29, 2026Preliminary proxy statementFormPRE 14A
- May 29, 2026Officer or director changeForm8-K
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 24, 2026Annual report (amendment)for the period to Dec 31, 2025Form10-K/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 2, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 2, 2026 | 8-K | Results of operations | Document |
| Oct 26, 2026 | 8-K | Results of operations | Document |
| Oct 9, 2026 | 8-K | Officer or director change | Document |
| Sep 23, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Sep 15, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 31, 2026 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares, other material events | Document |
| Aug 25, 2026 | 8-K | Other material events | Document |
| Aug 10, 2026 | 8-K | Material agreement entered | Document |
| Aug 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 3, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Results of operations | Document |
| Jul 24, 2026 | 8-K | Shareholder vote | Document |
| Jul 14, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jun 8, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Jun 8, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jun 8, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| May 29, 2026 | PRE 14A | Preliminary proxy statement | Document |
| May 29, 2026 | 8-K | Officer or director change | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 24, 2026 | 10-K/A | Annual report (amendment)for the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 12, 2003.
The full analysis
What do Jazz Pharmaceuticals's filings show?
The filings are where every one of Jazz Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.